California and Mississippi are next on the list
However, its not suitable for everyone, especially those with a history of thyroid cancer, pancreatitis, or certain hormonal disorders
Tranilast: a review of its therapeutic applications
In 2023, total commercial spending (gross) on GLP-1 drugs in Massachusetts is projected to surpass $270 million, more than double the spending in 2022, which was nearly $125 million
This opened a regulatory door for federally licensed 503B compounding pharmacies to make products containing semaglutide or tirzepatide, the same active ingredients brand-name GLP-1 drugs
During your free consultation, a licensed provider will assess your health needs to determine if Wegovy is the right fit for your weight-loss journey